Autopsy report · NCT02067416

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

“Funding agent withdrew funding”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Jenny C. Chang, MD

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Anthracycline based chemotherapy; taxane-based chemotherapy

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy
  “Funding withdrawn” (77% match in meaning)
• Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
  “funding was withdrawn” (77% match in meaning)
• Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation
  “Withdrawal of funding” (74% match in meaning)
• Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
  “Funding withdrawal” (72% match in meaning)
• Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
  “Funding withdrawn by sponsor” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.